GlassScriptPhysician profile
Walter David Leventhal
NPI 1124192869
$3,092.05
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,809 · 2020: $1,021 · 2021: $262.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $365.96 | 2019-2021 | |
| Novo Nordisk INC | $279.92 | 2019-2020 | |
| Pfizer INC. | $270.31 | 2019-2020 | |
| Glaxosmithkline, LLC. | $254.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $236.24 | 2019-2021 | |
| Abbvie INC. | $193.32 | 2019-2021 | |
| Allergan, INC. | $179.50 | 2019-2020 | |
| Lilly USA, LLC | $164.39 | 2019-2020 | |
| Amgen INC. | $154.86 | 2019-2021 | |
| Amarin Pharma, INC. | $114.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.66 | 2019 | |
| Astellas Pharma US INC | $86.06 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $81.93 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.49 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.02 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $49.53 | 2019-2021 | |
| Boston Scientific Corporation | $44.39 | 2019 | |
| Genentech USA, INC. | $36.47 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $33.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.57 | 2019 | |
| Antares Pharma, INC. | $24.17 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.14 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.64 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.08 | 2019 | |
| Upsher-Smith Laboratories LLC | $21.35 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.45 | 2019 | |
| Radius Health, INC. | $18.95 | 2019 | |
| Abbott Laboratories | $18.20 | 2021 | |
| Mission Pharmacal Company | $15.36 | 2019 | |
| Eisai INC. | $14.95 | 2020 | |
| Shire North American Group INC | $14.80 | 2019 | |
| Zyla Life Sciences, INC. | $14.67 | 2019 | |
| Optinose US, INC. | $14.54 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.20 | 2019 | |
| Hikma Pharmaceuticals USA | $12.60 | 2020 | |
| Medtronic Vascular, INC. | $11.91 | 2020 | |
| Sanofi Pasteur INC. | $11.84 | 2020 | |
| Currax Pharmaceuticals LLC | $11.63 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Leventhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.